Algomedix, Inc.

Mill Creek, WA 98012

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.95MM
Active Awards 2 valued at $1.03MM
First Award Date 08/01/11
Most Recent Award Date 09/21/17

2 Active Awards Valued at $1.03MM

Award Title Awarding Agency Phase Award amount Start Date End Date
Therapeutic TRPA1 Mechanism-Based Treatment of Chemotherapeutic-Induced Neuropathic Pain HHS 1 $291K 09/21/17 08/31/18
Development of a TRPA1 Antagonist Opioid-Sparing Analgesic for Chronic Pain HHS 2 $734K 09/01/17 08/31/18

Key Personnel

Last Name Name Awards Contact
Herz Jeff Mark Herz 5

5 Awards Won

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/21/17 - 08/31/18

Abstract Cancer patients treated with many widely used chemotherapeutic agents, including paclitaxel (PAC) and oxaliplatin (OXA), frequently develop chemotherapy-induced peripheral neuropathy (CIPN) that may lead to dose reduction, dosing schedule changes and termination of treatment. In some patients, acute peripheral neuropathy (PN) can trans...

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 09/01/17 - 08/31/18

Chronic pain affects over 100 million Americans. While opioids are recognized as the most effective drugs for the relief of pain, the US is now suffering from an epidemic of abuse, addiction and accidental overdose deaths resulting from prescription opioids. The goal of this proposal is develop a novel non-opioid analgesic drug devoid of addicti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/04/15 - 08/31/16

DESCRIPTION (provided by applicant): According to the United States Renal Data System, focal and segmental glomerulosclerosis (FSGS) is the most common histopathological finding in primary nephrotic syndrome patients with end-stage renal disease (ESRD). Treatment options in primary forms of FSGS are limited, poorly tolerated, and fail to produce...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/10/13 - 08/31/14

DESCRIPTION (provided by applicant): A safe and effective therapeutic for treatment of osteoarthritis (OA) represents a major unmet medical need. OA is the leading cause of disability in the US and pain is a predominant clinical feature. However, chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with potentially life-t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 08/01/11 - 07/31/13

DESCRIPTION (provided by applicant): Title: Analgesics Targeting TRPA1 for Treatment of Chronic Pain Abstract An effective treatment for chronic pain that is devoid of both addictive potential and abuse liability is a major unmet need in medicine today. These limitations drive the need for novel treatment options based on new molecular mecha...